Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Non-Current Liabilities: 2020-2022

Historic Other Non-Current Liabilities for Candel Therapeutics (CADL) over the last 3 years, with Dec 2022 value amounting to $1.9 million.

  • Candel Therapeutics' Other Non-Current Liabilities fell 90.64% to $433,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $433,000, marking a year-over-year decrease of 90.64%. This contributed to the annual value of $1.9 million for FY2022, which is 89.69% down from last year.
  • Per Candel Therapeutics' latest filing, its Other Non-Current Liabilities stood at $1.9 million for FY2022, which was down 89.69% from $18.3 million recorded in FY2021.
  • In the past 5 years, Candel Therapeutics' Other Non-Current Liabilities registered a high of $18.3 million during FY2021, and its lowest value of $1.9 million during FY2022.
  • Over the past 3 years, Candel Therapeutics' median Other Non-Current Liabilities value was $6.8 million (recorded in 2020), while the average stood at $9.0 million.
  • As far as peak fluctuations go, Candel Therapeutics' Other Non-Current Liabilities soared by 167.19% in 2021, and later plummeted by 89.69% in 2022.
  • Candel Therapeutics' Other Non-Current Liabilities (Yearly) stood at $6.8 million in 2020, then spiked by 167.19% to $18.3 million in 2021, then crashed by 89.69% to $1.9 million in 2022.